

**Consent to certain actions for the purposes of the Initial Enforcement Order made by the Competition and Markets Authority (CMA) on 1 April 2016**

**Completed acquisition by AAH Pharmaceuticals Limited (AAH) of Medical Advisory Services For Travellers Abroad Limited and Sangers (Northern Ireland) Limited (MASTA-Sangers)**

We refer to [redacted]'s email of 12 April 2016 requesting that the CMA consents to derogations to the Initial Enforcement Order of 1 April 2016 (the **Initial Order**). The terms defined in the Initial Order have the same meaning in this letter.

Under the Initial Order, save for written consent by the CMA, McKesson UK Finance I Limited and McKesson Corporation (together **McKesson Corporation**) and AAH are required to hold separate the MASTA-Sangers business from the McKesson Corporation business and refrain from taking any action which might prejudice a reference under section 22 of the Act or impede the taking of any remedial action following such a reference. After due consideration of your request for derogations from the Initial Order, based on the information received from you and in the particular circumstances of this case, AAH and McKesson Corporation may carry out the following actions, in respect of the specific paragraphs:

**Paragraphs 5(I)**

For the purpose of managing Companies House filing obligations, a Company Secretary requires access to certain company information that is confidential although will be made publicly available once filed. To enable [redacted] and employed by Lloyds Pharmacy Limited, to fulfil Companies House filing obligations as Company Secretary of certain entities within MASTA-Sangers, the CMA authorises [redacted] to have access to the documents and information necessary for Companies House filings, including annual returns and accounts, providing that the information and documents that [redacted] would have access to, will not be disclosed to any other individual carrying out activities within the McKesson Corporation and/or its subsidiaries. In order to comply with this requirement, [redacted] will sign a non-disclosure agreement (NDA) in a form approved by the CMA.